Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Ieq Capital LLC

Ieq Capital LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,090.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 27,206 shares of the company’s stock after acquiring an additional 24,921 shares during the quarter. Ieq Capital LLC owned about 0.09% of Medpace worth $9,039,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of Medpace by 18.5% during the third quarter. Blue Trust Inc. now owns 665 shares of the company’s stock worth $222,000 after purchasing an additional 104 shares during the period. Raymond James & Associates increased its holdings in Medpace by 1.7% in the 3rd quarter. Raymond James & Associates now owns 55,689 shares of the company’s stock worth $18,589,000 after buying an additional 954 shares during the period. Sequoia Financial Advisors LLC raised its position in Medpace by 32.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 798 shares of the company’s stock worth $266,000 after buying an additional 195 shares during the last quarter. Private Advisor Group LLC lifted its stake in Medpace by 29.7% during the 3rd quarter. Private Advisor Group LLC now owns 1,448 shares of the company’s stock valued at $483,000 after acquiring an additional 332 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in shares of Medpace by 38,432.9% in the 3rd quarter. International Assets Investment Management LLC now owns 57,414 shares of the company’s stock valued at $19,165,000 after acquiring an additional 57,265 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Stock Performance

MEDP stock opened at $344.85 on Friday. Medpace Holdings, Inc. has a one year low of $302.01 and a one year high of $459.77. The firm’s fifty day moving average is $343.28 and its 200 day moving average is $347.47. The firm has a market cap of $10.51 billion, a PE ratio of 27.30, a P/E/G ratio of 3.77 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.